Stefano Pulini

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 788 citations

Medicine, Pharmacology, Pharmacotherapy +15

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Antonio Palumbo, Michèle Cavo, Elena Zamagni et al. · Journal of Clinical Oncology · 2011 · 322 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Francesca Gay, Stefania Oliva, Maria Teresa Petrucci et al. · The Lancet Oncology · 2015 · 313 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Valeria Magarotto, Sara Bringhen, Massimo Offidani et al. · Blood · 2016 · 94 citations · Full text

Medicine, Hematology, Oncology +15

Long‐term experience with low‐dose interferon‐<i>α</i> and PUVA in the management of early mycosis fungoides

Serena Rupoli, Gaia Goteri, Stefano Pulini et al. · European Journal Of Haematology · 2005 · 72 citations

Medicine, Dermatology, Oncology +8